SenzaGen update: Continued very strong sales growth in Q3 2022
SenzaGen’s Q3 sales 2022 more than tripled year-on-year to SEK 9.0 million, driven by strong organic growth with new and returning major global customers combined… Read More
SenzaGen
SenzaGen obtains OECD approval for GARD®skin
SenzaGen today announced that the Company has obtained approval from the OECD for GARD®skin as a test guideline for non-animal skin sensitization. This means that… Read More
SenzaGen broadens non-animal offering for medical devices with more tests and tailored consulting services
– strengthens market presence and realizes synergies from acquisition Starting in February 2022, SenzaGen provides an expanded and more complete in-vitro toxicology test offering for… Read More
SenzaGen receives SEK 1m follow-on order for GARD®skin Dose-Response from one of the world’s largest cosmetics companies
SenzaGen secured another project to test ingredients in cosmetics products from one of the largest cosmetics companies in the world. The new order is valued… Read More
